The National Comprehensive Cancer Network (NCCN) has added a new value criterion to its clinical practice guidelines in the form of “Evidence Blocks” for the evaluation of treatment options.
“Everolimus is the first targeted agent to show robust antitumor activity with acceptable tolerability across a broad spectrum of NETs,” said James C. Yao, MD.
“Especially for average-risk women, decisions to undergo regular mammography screening must also consider the harms of mammography,” stated Nancy L. Keating, MD, MPH, and Lydia E. Pace, MD, MPH.
To take full benefit of advances made possible by Next-Generation Sequencing, more American patients with cancer must be involved in clinical trials, said Raju Kucherlapati, PhD, Professor of Genetics, Harvard Medical School, at the Fifth Annual Conference of the Association for Value-Based Cancer Care.
  • Imlygic, First-of-Its-Kind Oncolytic Virus Therapy Approved for Melanoma
  • Yondelis a New Treatment Option for Patients with Soft-Tissue Sarcoma
  • Onivyde Receives Expedited Approval for Metastatic Pancreatic Cancer
  • Abemaciclib Receives Breakthrough Therapy Status for Refractory Metastatic Breast Cancer
  • Opdivo Gets Second Indication for Metastatic Lung Cancer
  • Medicare Will Now Reimburse Physicians for End-of-Life Discussions with Patients
  • New Scoring System Can Improve Lung Cancer Diagnosis
  • First Consensus Statement on High-Quality Palliative Care Issued by ASCO/AAHPM
In October, the National Comprehensive Cancer Network (NCCN) released its first set of “flash cards” or “Evidence Blocks” as a tool for evaluating treatment decisions, seeking to solve a drug cost problem that does not exist, by adding to a problem that does: insurers shifting the cost of cancer treatment to patients. In so doing, the NCCN could inadvertently increase the rate at which patients with cancer choose assisted suicide.
Vienna, Austria—Patients with advanced, pretreated renal-cell carcinoma (RCC) who have limited treatment options got good news from 2 important practice-changing trials, CheckMate 025 and METEOR, which were presented as late-breaking abstracts at the 2015 European Cancer Congress (ECC). CheckMate 025 showed a survival benefit for nivolumab (Opdivo) over standard therapy with everolimus (Afinitor) in patients with previously treated advanced RCC. This is the first trial to show a survival benefit for an immune checkpoint inhibitor after standard therapy has failed. METEOR showed that cabozantinib (Cometriq) nearly doubled progression-free survival (PFS) compared with standard everolimus in patients with advanced RCC whose disease progressed with previous vascular endothelial growth factor (VEGF) receptor (VEGFR)-targeted therapy.
San Francisco, CA—Magnetic resonance imaging (MRI) screening of women who are at average risk for breast cancer had a mean additional cancer diagnosis yield of 15.8 per 1000 patients, surpassing the yields for digital breast tomosynthesis and ultrasound in a new study. The results were presented at the 2015 Breast Cancer Symposium, by Christiane K. Kuhl, MD, Department of Diagnostic and Interventional Radiology, RWTH Aachen University, Germany. This suggests that breast MRI screening alone every 3 years may be sufficient for women at average risk.
A study from the Centers for Disease Control and Prevention documented an average 38% colorectal cancer (CRC) screening rate among people aged 40 to 49 years, and a 69.7% rate in those aged ≥50 years with a first-degree relative with CRC. An earlier analysis of National Health Interview Survey (NHIS) data from 2005 and 2010 showed that first-degree relatives of patients with CRC were 70% more likely to have a colonoscopy than their counterparts.
Page 1 of 2
Results 1 - 10 of 19
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology